AUPH | Aurinia Pharmaceuticals Inc.

Healthcare | Biotechnology | Canada | NASD

Index	-	P/E	-	EPS (ttm)	-0.68	Insider Own	0.10%	Shs Outstand	142.64M	Perf Week	15.36%
Market Cap	1.43B	Forward P/E	-	EPS next Y	-0.42	Insider Trans	-32.80%	Shs Float	132.88M	Perf Month	-9.69%
Income	-96.80M	PEG	-	EPS next Q	-0.18	Inst Own	40.50%	Short Float / Ratio	11.68% / 5.07	Perf Quarter	15.49%
Sales	146.80M	P/S	9.72	EPS this Y	45.50%	Inst Trans	9.51%	Short Interest	15.52M	Perf Half Y	104.71%
Book/sh	2.74	P/B	3.81	EPS next Y	38.20%	ROA	-20.40%	Target Price	16.00	Perf Year	-8.26%
Cash/sh	2.64	P/C	3.95	EPS next 5Y	-	ROE	-23.60%	52W Range	4.07 - 13.41	Perf YTD	141.67%
Dividend	-	P/FCF	-	EPS past 5Y	3.70%	ROI	-27.90%	52W High	-22.18%	Beta	1.18
Dividend %	-	Quick Ratio	9.30	Sales past 5Y	216.80%	Gross Margin	96.00%	52W Low	156.51%	ATR	0.60
Employees	300	Current Ratio	10.10	Sales Q/Q	59.30%	Oper. Margin	-70.30%	RSI (14)	51.93	Volatility	5.73% 5.50%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	30.80%	Profit Margin	-65.90%	Rel Volume	0.80	Prev Close	9.91
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 04 BMO	Payout	-	Avg Volume	3.06M	Price	10.44
Recom	2.10	SMA20	0.78%	SMA50	-2.25%	SMA200	29.52%	Volume	2,463,768	Change	5.35%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-22	Downgrade	Oppenheimer	Outperform → Perform
May-05-22	Resumed	Cantor Fitzgerald	Overweight	$34 → $25
Dec-10-21	Upgrade	Oppenheimer	Perform → Outperform	$33 → $31
Oct-28-21	Downgrade	Oppenheimer	Outperform → Perform	$32
Jan-25-21	Reiterated	H.C. Wainwright	Buy	$30 → $35
Nov-03-20	Reiterated	H.C. Wainwright	Buy	$34 → $28
Jun-17-20	Initiated	BTIG Research	Buy	$20
May-05-20	Initiated	Cowen	Outperform
Jan-10-20	Initiated	Jefferies	Buy	$27
Dec-16-19	Reiterated	H.C. Wainwright	Buy	$25 → $32
Mar-16-18	Reiterated	Cantor Fitzgerald	Overweight	$14 → $16
Feb-08-18	Initiated	RBC Capital Mkts	Outperform	$9
Oct-30-17	Reiterated	H.C. Wainwright	Buy	$10 → $12
May-18-17	Reiterated	H.C. Wainwright	Buy	$12 → $10
Apr-11-17	Initiated	Cantor Fitzgerald	Overweight	$14
Mar-22-17	Reiterated	FBR & Co.	Outperform	$9 → $11
Dec-30-16	Reiterated	H.C. Wainwright	Buy	$10 → $8
Aug-17-16	Reiterated	H.C. Wainwright	Buy	$7 → $10
Jun-30-16	Initiated	H.C. Wainwright	Buy	$7
May-08-15	Initiated	MLV & Co	Buy	$9

Show Previous Ratings

Jun-06-23 08:11AM	Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Shares Lagging The Industry But So Is The Business (Simply Wall St.) +5.35%
Jun-01-23 09:00AM	LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone (Business Wire)
May-26-23 05:16PM	Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees (Business Wire)
May-23-23 06:56AM	Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Shift From Loss To Profit (Simply Wall St.)
May-17-23 12:14PM	Aurinia Announces 2023 Annual General Meeting Results (Business Wire)
12:00PM	Loading…
May-11-23 12:00PM	Here's Why Aurinia Pharmaceuticals (AUPH) is a Great Momentum Stock to Buy (Zacks)
May-09-23 06:02AM	News Flash: Analysts Just Made A Sizeable Upgrade To Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Forecasts (Simply Wall St.)
06:00AM	Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference (Business Wire)
May-04-23 07:15AM	Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:11AM	Aurinia: Q1 Earnings Snapshot (AP Finance)
06:00AM	Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results (Business Wire)
May-03-23 07:51AM	Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis (Business Wire)
May-02-23 04:36PM	ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote "FOR" ALL Company Director Nominees at 2023 Annual General Meeting (Business Wire)
12:00PM	Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin) (Business Wire)
Apr-28-23 06:30AM	Glass Lewis Recommends Aurinia Shareholders Vote "FOR" ALL Company Director Nominees at 2023 Annual Meeting (Business Wire)
11:30AM	Loading…
Apr-26-23 11:30AM	3 Biotechs That Might Get Bought Out in 2023 (Motley Fool)
Apr-25-23 11:00AM	Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys (Business Wire)
Apr-24-23 05:10PM	Is Aurinia Pharmaceuticals Up for Grabs? Shareholder Suggests a Quick Sale for a Bigger Payday (Benzinga)
06:00AM	Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023 (Business Wire)
Apr-12-23 12:34PM	Aurinia (AUPH) Up 11% on Issue of New Additional Lupkynis Patent (Zacks)
Apr-11-23 02:41PM	Why Aurinia Pharmaceuticals Stock Is Glowing Green Today (Motley Fool) +10.84%
10:26AM	Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office (Business Wire)
05:39AM	3 Stocks That Already Doubled in 2023 and Could Keep Climbing (Motley Fool)
Apr-05-23 06:30AM	Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial (Business Wire)
Apr-04-23 06:42AM	We Think Aurinia Pharmaceuticals (NASDAQ:AUPH) Can Easily Afford To Drive Business Growth (Simply Wall St.)
Apr-03-23 04:00PM	Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.84%
Mar-27-23 04:52AM	Aurinia (AUPH) Surges 11.0%: Is This an Indication of Further Gains? (Zacks)
Mar-09-23 09:17AM	Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-08-23 05:09AM	Independent Chairman of the Board George Milne Just Bought 40% More Shares In Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Simply Wall St.) +9.96%
Mar-06-23 04:00PM	Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
07:15AM	Loading…
Feb-28-23 07:15AM	Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +9.12%
06:00AM	Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates (Business Wire)
Feb-24-23 06:00AM	Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference (Business Wire)
Feb-23-23 07:46AM	4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates (Zacks) +6.19%
Feb-22-23 10:00AM	Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-21-23 10:00AM	Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -5.01%
Feb-19-23 07:30AM	This Pharma Is Starting to Recover Nicely (TheStreet.com)
Feb-17-23 05:42AM	Both individual investors who control a good portion of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) along with institutions must be dismayed after last week's 9.4% decrease (Simply Wall St.) +7.62%
Feb-07-23 04:00PM	Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023 (Business Wire)
Feb-06-23 04:00PM	Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-27-23 06:40PM	Blackstone Stock Is a Good Investment, Even in a Downbeat Economy (Barrons.com)
Jan-25-23 01:00PM	Aurinia Announces PTAB Has Terminated Inter Partes Review (Business Wire) +10.23%
Jan-24-23 04:00PM	Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office (Business Wire)
Jan-16-23 05:39AM	Investors ignore increasing losses at Aurinia Pharmaceuticals (NASDAQ:AUPH) as stock jumps 21% this past week (Simply Wall St.)
Jan-06-23 04:49PM	Why Shares of Aurinia Pharmaceuticals Soared This Week (Motley Fool) +9.58%
06:00AM	Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results (Business Wire)
Jan-04-23 04:05PM	Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference (Business Wire) +13.13%
04:47AM	Aurinia (AUPH) Soars 37.5%: Is Further Upside Left in the Stock? (Zacks)
Jan-03-23 04:55PM	Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +37.50%
09:12AM	Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals (Business Wire)
Dec-05-22 04:05PM	Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-30-22 04:05PM	Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis (Business Wire)
Nov-08-22 08:39AM	Aurinia Pharmaceuticals Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.) +6.53%
Nov-04-22 12:12PM	Newsflash: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Have Been Trimming Their Revenue Forecasts (Simply Wall St.)
Nov-03-22 07:25AM	Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -31.93%
06:00AM	Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results (Business Wire)
Oct-30-22 10:45AM	Insiders of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reaped rewards after their US$556k investment jumped another US$272k (Simply Wall St.)
Oct-28-22 05:30PM	Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022 (Business Wire)
Oct-27-22 12:00PM	Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022 (Business Wire)
Oct-21-22 09:12AM	Aurinia (AUPH) Moves 13.1% Higher: Will This Strength Last? (Zacks) -12.78%
Oct-09-22 09:40AM	Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Path To Profitability (Simply Wall St.)
Oct-03-22 04:05PM	Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-21-22 01:41PM	10 Stocks to Sell Now According to Orkun Kilics Berry Street Capital (Insider Monkey)
Sep-20-22 04:05PM	Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022 (Business Wire)
12:04PM	Aurinia's (AUPH) Oral Lupus Drug Lupkynis Gets European Approval (Zacks)
Sep-19-22 11:15AM	Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis (Business Wire)
Sep-05-22 06:22AM	Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) market cap dropped US$71m last week; individual investors who hold 57% were hit as were institutions (Simply Wall St.)
Aug-08-22 11:27AM	Those who invested in Aurinia Pharmaceuticals (NASDAQ:AUPH) three years ago are up 48% (Simply Wall St.)
Aug-04-22 11:58AM	Why Aurinia Pharmaceuticals Stock Briefly Spiked Today (Motley Fool)
07:35AM	Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:00AM	Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results (Business Wire)
Aug-01-22 04:05PM	Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-27-22 12:22PM	Why Aurinia Pharmaceuticals Stock Is Sliding Today (Motley Fool)
Jul-26-22 02:00PM	Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review (Business Wire) -16.00%
Jul-25-22 04:07PM	Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022 (Business Wire)
Jul-22-22 06:05AM	Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe (Business Wire)
Jul-15-22 04:10PM	Aurinia Pharmaceuticals Skids With Its Buyout Thesis Hanging By A Thread (Investor's Business Daily) -9.41%
12:01PM	Why Aurinia Pharmaceuticals Stock Is In Retreat Today (Motley Fool)
Jul-14-22 04:10PM	Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance (Business Wire)
Jul-05-22 03:17AM	Aurinia (AUPH) Moves 13.3% Higher: Will This Strength Last? (Zacks) +8.60%
Jul-01-22 04:46PM	Why Aurinia Pharmaceuticals Stock Perked Up Today (Motley Fool) +13.33%
Jun-06-22 04:05PM	Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.01%
Jun-03-22 07:05AM	Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations (Business Wire)
May-20-22 12:07PM	Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress (Business Wire)
May-16-22 07:17AM	Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress (Business Wire)
May-10-22 07:15AM	Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +25.99%
06:00AM	Aurinia Reports First Quarter 2022 Financial and Operational Results (Business Wire)
May-06-22 04:05PM	Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022 (Business Wire) -6.36%
May-02-22 04:05PM	Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022 (Business Wire) +5.83%
04:00PM	3 Healthcare Companies With Revenue Spiking 100% or More (Motley Fool)
08:12AM	Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Profit Outlook (Simply Wall St.)
Apr-28-22 03:02PM	Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-19-22 07:10AM	Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis (Business Wire)
Apr-04-22 04:11PM	Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings (Business Wire)
Mar-04-22 04:37AM	Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.)
Mar-03-22 04:31PM	Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire) -6.28%
Mar-01-22 04:49AM	While Aurinia Pharmaceuticals (NASDAQ:AUPH) shareholders have made 129% in 5 years, increasing losses might now be front of mind as stock sheds 29% this week (Simply Wall St.)
Feb-28-22 04:28PM	Aurinia Stock Takes a Hit, but Is It Warranted? Analyst Weighs In (TipRanks) -24.26%
04:03PM	Why Aurinia Pharmaceuticals Tumbled Despite Its 'Aggressive' 2022 Outlook (Investor's Business Daily)
09:43AM	Why Aurinia Pharmaceuticals Stock Is Crashing Today (Motley Fool)

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jayne David R.W.	Director	May 23	Sale	11.26	8,733	98,334	49,310	May 23 05:19 PM
MacKay-Dunn R. Hector	Director	May 23	Sale	11.26	4,818	54,251	24,225	May 23 05:16 PM
Leversage Jill	Director	May 23	Sale	11.26	4,815	54,217	18,528	May 23 05:14 PM
Billen Daniel	Director	May 23	Sale	11.26	4,650	52,359	33,393	May 23 05:17 PM
Hagan Joseph P	Director	May 19	Sale	10.58	272	2,878	11,961	May 23 05:18 PM
MILNE GEORGE M JR	Director	Mar 02	Buy	8.91	20,000	178,284	70,000	Mar 06 04:29 PM
Greenleaf Peter	Chief Executive Officer	Mar 02	Sale	8.94	32,750	292,785	982,968	Mar 06 04:27 PM
Robertson Stephen P.	EVP, General Counsel	Mar 02	Sale	8.94	19,402	173,454	303,364	Mar 06 04:29 PM
Miller Joseph M	Chief Financial Officer	Mar 02	Sale	8.94	11,296	100,986	331,214	Mar 06 04:29 PM
Donley Matthew Maxwell	Ex VP, Internal Operations	Nov 21	Buy	4.66	10,000	46,600	27,927	Nov 23 04:04 PM
Habig Scott Michael	Chief Commercial Officer	Nov 09	Buy	5.01	5,000	25,075	5,000	Nov 14 04:31 PM
Martin Michael Robert	Chief Business Officer	Nov 07	Buy	5.16	30,000	154,800	89,512	Nov 09 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AUPH | Aurinia Pharmaceuticals Inc.

Upgrade your FINVIZ experience